Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2016, Article ID 8987976, 7 pages
http://dx.doi.org/10.1155/2016/8987976
Research Article

Distribution of Hepatitis C Risk Factors and HCV Treatment Outcomes among Central Canadian Aboriginal

1Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
2The Ottawa Hospital Research Institute, Ottawa, ON, Canada
3The Division of Infectious Diseases, Department of Medicine, University of Ottawa, Ottawa, ON, Canada

Received 15 October 2015; Accepted 7 November 2015

Copyright © 2016 Parmvir Parmar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Baden, J. K. Rockstroh, and M. Buti, “Natural history and management of hepatitis C: does sex play a role?” Journal of Infectious Diseases, vol. 209, supplement 3, pp. S81–S85, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Hajarizadeh, J. Grebely, and G. J. Dore, “Epidemiology and natural history of HCV infection,” Nature Reviews Gastroenterology and Hepatology, vol. 10, no. 9, pp. 553–562, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. J. McCombs, T. Matsuda, I. Tonnu-Mihara et al., “The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a department of veterans affairs clinical registry,” JAMA Internal Medicine, vol. 174, no. 2, pp. 204–212, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. R. P. Myers, M. Krajden, M. Bilodeau et al., “Burden of disease and cost of chronic hepatitis C infection in Canada,” Canadian Journal of Gastroenterology & Hepatology, vol. 28, no. 5, pp. 243–250, 2014. View at Google Scholar
  5. R. J. Harris, B. Thomas, J. Griffiths et al., “Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios,” Journal of Hepatology, vol. 61, no. 3, pp. 530–537, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. F. S. Mennini, A. Marcellusi, M. Andreoni, A. Gasbarrini, S. Salomone, and A. Craxì, “Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy,” ClinicoEconomics and Outcomes Research, vol. 6, no. 1, pp. 303–310, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. Z. M. Younossi, M. Otgonsuren, L. Henry et al., “Inpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States,” Journal of Viral Hepatitis, vol. 22, no. 2, pp. 137–145, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. C. L. Cooper, R. J. Bailey, V. G. Bain et al., “Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians,” Canadian Journal of Gastroenterology, vol. 22, no. 8, pp. 677–680, 2008. View at Google Scholar · View at Scopus
  9. K. J. P. Craib, P. M. Spittal, S. H. Patel et al., “Prevalence and incidence of hepatitis C virus infection among aboriginal young people who use drugs: results from the Cedar Project,” Open Medicine, vol. 3, no. 4, pp. e220–e227, 2009. View at Google Scholar · View at Scopus
  10. P. M. Spittal, M. E. Pearce, N. Chavoshi et al., “The Cedar Project: high incidence of HCV infections in a longitudinal study of young Aboriginal people who use drugs in two Canadian cities,” BMC Public Health, vol. 12, article 632, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Y. Shaw, K. N. Deering, A. M. Jolly, and J. L. Wylie, “Increased risk for hepatitis C associated with solvent use among Canadian Aboriginal injection drug users,” Harm Reduction Journal, vol. 7, article 16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. H. X. Wu, J. Wu, T. Wong et al., “Incidence and risk factors for newly acquired hepatitis C virus infection among Aboriginal versus non-Aboriginal Canadians in six regions, 1999–2004,” The European Journal of Clinical Microbiology & Infectious Diseases, vol. 26, no. 3, pp. 167–174, 1999. View at Google Scholar
  13. M. Alavi, J. D. Raffa, G. D. Deans et al., “Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents,” Liver International, vol. 34, no. 8, pp. 1198–1206, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Dawood, G. Smart, M. Wood, H.-X. Wu, S. Paton, and J. Wu, “Hepatitis C virus infection among First Nation and non-First Nation people in Manitoba, Canada—a public health laboratory study,” Canadian Journal of Microbiology, vol. 52, no. 10, pp. 999–1005, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Y. Minuk and J. Uhanova, “Viral hepatitis in the Canadian Iuit and First Nations populations,” Canadian Journal of Gastroenterology, vol. 17, no. 12, pp. 707–712, 2003. View at Google Scholar · View at Scopus
  16. J. D. Rempel and J. Uhanova, “Hepatitis C virus in American Indian/Alaskan native and Aboriginal peoples of North America,” Viruses, vol. 4, no. 12, pp. 3912–3931, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. J. D. Scott and N. Garland, “Chronic liver disease in aboriginal north Americans,” World Journal of Gastroenterology, vol. 14, no. 29, pp. 4607–4615, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Suryaprasad, K. K. Byrd, J. T. Redd, D. G. Perdue, M. M. Manos, and B. J. McMahon, “Mortality caused by chronic liver disease among American Indians and Alaska Natives in the United States, 1999–2009,” American Journal of Public Health, vol. 104, supplement 3, pp. S350–S358, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Alavi, J. Grebely, M. Micallef et al., “Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study,” Clinical Infectious Diseases, vol. 57, supplement 2, pp. S62–S69, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Y. Minuk, M. O'Brien, K. Hawkins et al., “Treatment of chronic hepatitis C in a Canadian Aboriginal population: results from the PRAIRIE study,” Canadian Journal of Gastroenterology, vol. 27, no. 12, pp. 707–710, 2013. View at Google Scholar · View at Scopus
  21. M. B. Klein, K. C. Rollet, S. Saeed et al., “HIV and hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality,” HIV Medicine, vol. 14, no. 1, pp. 10–20, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Pampalon, D. Hamel, P. Gamache, and G. Raymond, “A deprivation index for health planning in Canada,” Chronic Diseases in Canada, vol. 29, no. 4, pp. 178–191, 2009. View at Google Scholar · View at Scopus
  23. T. Berg, C. Sarrazin, E. Herrmann et al., “Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy,” Hepatology, vol. 37, no. 3, pp. 600–609, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Imran, S. Manzoor, J. Ashraf et al., “Role of viral and host factors in interferon based therapy of hepatitis C virus infection,” Virology Journal, vol. 10, article 299, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. S. B. Rourke, M. Sobota, R. Tucker et al., “Social determinants of health associated with hepatitis C co-infection among people living with HIV: results from the Positive Spaces, Healthy Places study,” Open Medicine, vol. 5, no. 3, pp. e120–e131, 2011. View at Google Scholar · View at Scopus
  26. Public Health Agency of Canada, “HIV/AIDS Epi updates: national HIV prevalence and incidence estimates for 2011,” in Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, 2014. View at Google Scholar
  27. S. B. Missiha, M. Ostrowski, and E. J. Heathcote, “Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors,” Gastroenterology, vol. 134, no. 6, pp. 1699–1714, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. J. D. Rempel, K. Hawkins, E. Lande, and P. Nickerson, “The potential influence of KIR cluster profiles on disease patterns of Canadian Aboriginals and other indigenous peoples of the Americas,” European Journal of Human Genetics, vol. 19, no. 12, pp. 1276–1280, 2011. View at Publisher · View at Google Scholar · View at Scopus